L'Oreal and Estee Lauder are now framing aging as a measurable biological process, betting their multibillion-dollar portfolios on longevity science that promises to rewrite how skincare is developed, sold, and regulated.
L'Oreal is betting big on longevity with its Longevity Integrative Science platform, anchored by the proprietary Longevity AI Cloud TM that analyses over 260 biomarkers using twelve hallmarks of aging to predict ingredient impact, and has applied this to Cell BioPrint Skin Age Test and Lancome Absolue Longevity products.
Estee Lauder takes a luxury route through its Skin Longevity Institute, focusing on sirtuin biology, delivery systems and academic collaborations, repositioning Re-Nutriv with SIRTIVITY-LPTM technology and citing peer-reviewed papers.
Across the market, brands from Guerlain to Nivea to Paula's Choice are adopting longevity language, promising cellular vitality, epigenetic resetting or reduced biological age, but many claims rely on narrative rather than rigorous evidence.
Regulatory eyes are widening. The FTC challenged L'Oreal's gene-targeting claims in 2014, leading to a settlement, and today the agency warns that referencing sirtuin activation or mitochondrial repair may trigger drug classification and enforcement actions. The NAD referred HigherDOSE for non-participation in inquiries about its red-light masks, highlighting intensified scrutiny.
Independent scientists stress that measurable skin aging requires longitudinal data and validated biomarkers; current AI-driven skin analysis tools often assess surface appearance only, not underlying biological drivers.
Advanced diagnostics like L'Oreal's Cell BioPrint, which measures protein biomarkers, and sub-surface imaging technologies promise deeper insight, but the clinical significance and reproducibility of these tools remain unvalidated.
Dr. Barzilai notes that true longevity is a multi-system, years-long effort using serial biomarkers and functional measures, and that skincare must demonstrate specific, time-bound efficacy rather than borrow scientific terminology.
The industry's challenge is to separate cosmetic outcomes from genuine biological effects, building honest claims supported by rigorous, peer-reviewed studies as consumer and regulator expectations rise.